PBAC's latest decision on Etoricoxib: Not recommended (2008). Considered for Symptomatic treatment of the signs and symptoms of osteoarthritis.
PBAC outcome
Not recommended
2008
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2007
Submissions
2
2007 → 2008
Eligible population
patients with symptomatic treatment of the signs and symptoms of osteoarthritis
Therapy area
Pain
Evidence base
RCT, cost-minimisation
Primary endpoint
Pain reduction, improvement in function, patient global assessment of disease status
Key trials
P007, P076, P077
Comparator
celecoxib 200 mg
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no ICER calculated
Why PBAC said no
Reasons cited in the latest PSD: Lack of demonstrated clinical need, inferior safety profile with increased hypertension-related adverse events compared to celecoxib, non-inferiority in safety not established, dose-related blood pressure effects of etoricoxib raise further concerns for 60 mg dose, trial populations non-hypertensive or adequately controlled at baseline limiting applicability, quality use of medicines program lacked robust evidence